APA (7th ed.) Citation

D, A., MIR, R., HA, S., N, N., MD, H., RN, E., . . . PBT, S. (2026). Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in peripheral artery disease-a systematic review and meta-analysis. Current medical research and opinion, 42(2), 385. https://doi.org/10.1080/03007995.2026.2662127

Chicago Style (17th ed.) Citation

D, Ariyanti, et al. "Beyond Maximally Tolerated Statins: PCSK9 Inhibitors as a Critical Adjunct for Cardiovascular Risk Reduction in Peripheral Artery Disease-a Systematic Review and Meta-analysis." Current Medical Research and Opinion 42, no. 2 (2026): 385. https://doi.org/10.1080/03007995.2026.2662127.

MLA (9th ed.) Citation

D, Ariyanti, et al. "Beyond Maximally Tolerated Statins: PCSK9 Inhibitors as a Critical Adjunct for Cardiovascular Risk Reduction in Peripheral Artery Disease-a Systematic Review and Meta-analysis." Current Medical Research and Opinion, vol. 42, no. 2, 2026, p. 385, https://doi.org/10.1080/03007995.2026.2662127.